Public health researchers are questioning the lack of evidence behind the Government’s plans to legalise nicotine pouches, raising concerns about potential health risks, youth uptake and the influence of commercial interests.
Recently released Cabinet material confirms that the Government is progressing legislation to allow the commercial sale of nicotine pouches and other novel oral nicotine products (ONPs) in Aotearoa New Zealand.
A new Briefing published by the Public Health Communication Centre (PHCC) examines the decision and questions whether the potential risks and benefits of these products have been adequately assessed.
The Cabinet paper argues that making lower-risk nicotine alternatives legally available could help achieve smokefree goals. However, it provides no supporting evidence for this claim and does not include previous Ministry of Health advice against legalising ONPs, which highlighted potential health harms, nicotine dependence and the risk of uptake among children and adolescents.
Lead author PHCC Science Lead Calvin Cochran says there are important questions about the lack of evidence informing the decision. “There needs to be a robust assessment of the potential harms and benefits of ONPs before proceeding with any legislation.”
Nicotine pouches are small sachets placed between the lip and gum, allowing nicotine to be absorbed through the mouth. Major tobacco companies, including Philip Morris International and British American Tobacco, are among the global manufacturers and promoters of these products.
The companies generally market ONPs as products for adult nicotine consumers rather than smoking cessation aids. However, their industry allies have argued that legalising them would provide smokers with lower-risk alternatives.
The Briefing notes that established and evidence-based nicotine replacement therapies, including patches, gum and lozenges, are already available to support people to stop smoking. Vaping products are also widely available.
There are also growing international concerns about the marketing of ONPs to young people. In May this year, the World Health Organization warned that nicotine pouches were being aggressively marketed to adolescents and young people and recommended that countries introduce restrictions and bans.
Several countries are responding to concerns about youth uptake and marketing. Australia has recently banned the personal importation of ONPs, while Canada, the United Kingdom and France have introduced additional safeguards.
Calvin Cochran says New Zealand needs to consider these international experiences when deciding whether to introduce another category of commercially available nicotine products.
“New Zealand risks repeating the experience of youth vaping if these products are allowed to be widely marketed,” Cochran says.